Insider buying last 90 days
No open-market insider purchases were filed for DGX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every DGX insider filing, plotted on the chart in Gekko.Open DGX in Gekko
NYSE: DGX
Quest Diagnostics (DGX) Stock Analysis & Forecast
$246.45−1.00 (−0.4%)
Close on Sep 18, 2026. Page updated Sep 19, 9:16 pm ET.
Gekko Brief
AI summaryQuest Diagnostics (DGX) closes at $246.45, down 0.4% on the day, and sits above both its 50-day average of $232.63 and its 200-day average of $203.42, with the shorter average above the longer one. The GekkoIndex reads 49.4, placing it in the Neutral zone, down 10.2 points over the last five readings. The stock trades 12.4% above Gekko Fair Value of $219.23, and its close is near the 52-week high of $248.70, well above the 52-week low of $171.18.
Recent coverage centers on the stock's move to a fresh 52-week high, trading as high as $248.65 this week, alongside commentary on momentum and fundamentals following that milestone. Quest Diagnostics also published a national survey finding that nine in ten registered voters are concerned that Medicare lab payment cuts will harm patient access to diagnostic testing, with a bipartisan majority wanting Congress to pass the RESULTS Act before further cuts take effect in January 2027. Separately, a 13F filing showed Corient Private Wealth LP reduced its DGX position by 13.3%, selling 5,233 shares to leave it holding 34,092 shares.
Looking ahead, the next earnings report is due 20 October 2026 before the open, 30 days out and beyond a typical 20-trading-day hold; the last report on 23 July 2026 beat estimates ($3.12 versus $2.81) and produced an 8.6% reaction, part of a streak of 8 beats in 8 quarters. No insider, Congress, or unusual options activity appears in their respective windows. Seasonality over 5 years shows a -1.5% average return across the next 20 trading days from this point, rising in 2 of those years, worth noting alongside the current gap to Gekko Fair Value.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $246.45200-day averageGekko Fair Value $219.23
Key stats
- Market cap
- $27.20B
- P/E ratio
- 26.3
- Forward P/E
- 20.6
- EPS, TTM
- $9.41
- Revenue, TTM
- $11.56B
- Profit margin
- 9.2%
- Dividend yield
- 1.34%
- Beta
- 0.55
- Volume
- 1.93M avg 996,869
- 1-year return
- +35.2%
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4%
- 50-day average
- $232.63
- 200-day average
- $203.42
- Next earnings
- Oct 20 before open
- Shares outstanding
- 110.4M
Quest Diagnostics swing-trade checklist
Quest Diagnostics scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $246.45 is above the 50-day ($232.63) and 200-day ($203.42) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
49.4, Neutral
Reading 49.4 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
12.4% above
Price is 12.4% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 30 days
Next report Oct 20, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−1.5% on average
From this point in the calendar, the next 20 trading days averaged −1.5% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Quest Diagnostics stock chart and price history
Quest Diagnostics closed at $246.45 on Sep 18, 2026, +35.2% over the past year, inside a 52-week range of $171.18 to $248.70.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +1.9%
- 3 months
- +26.4%
- 6 months
- +26.9%
- 1 year
- +35.2%
The full DGX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DGX in Gekko
Follow Quest Diagnostics through every session
Put DGX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track DGX in GekkoFree for 7 days. No credit card required.
About Quest Diagnostics
Quest Diagnostics runs testing laboratories that analyze patient samples and turn them into clinical information for doctors, hospitals, and other healthcare groups, both within the United States and in other countries. Its work spans everyday lab work along with more specialized clinical and pathology testing, and the company has built its reputation around this kind of diagnostic reporting.
Alongside its main brand, Quest Diagnostics also operates under names such as AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum, which help it connect with different segments of the healthcare world, including health plans, employers, integrated care networks, and direct medical providers. To get samples and results moving, it relies on a mix of lab sites, patient service locations, in-office blood draw staff, call centers, and traveling health workers such as nurses and paramedics. The company also performs risk evaluation work for life insurers and builds software and IT tools used by clinicians and healthcare organizations.
Quest Diagnostics traces back to 1967 and keeps its headquarters in Secaucus, New Jersey. Its stock trades on the NYSE under the ticker DGX.
- Listed
- NYSE
- Sector
- Health services
- Industry
- Services to the health industry
- Website
- questdiagnostics.com
Quest Diagnostics GekkoIndex: the smart money zone
Quest Diagnostics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 49.4, in the Neutral zone, down 10.2 points over five sessions.
49.4Neutral
Down 10.2 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 18 | +1.0% | +1.6% | ||
| Accumulation | 180 | +1.1% | +4.0% | ||
| Neutral (current zone) | 433 | +0.3% | +1.3% | ||
| Distribution | 30 | −1.0% | +1.3% | ||
| Selling | 1 | Too few readings yet | |||
Average DGX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the DGX price, zone by zone.Track DGX in Gekko
Is Quest Diagnostics stock overvalued? Gekko Fair Value
Quest Diagnostics trades 12.4% above Gekko Fair Value of $219.23, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Quest Diagnostics shares are worth, recalculated every trading day.
$219.23
Gekko Fair Value, Sep 18, 2026
12.4% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open DGX in Gekko
Quest Diagnostics insider and Congress trading
No open-market insider purchases were filed for Quest Diagnostics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in DGX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for DGX, plotted on the chart in Gekko.Open DGX in Gekko
Buybacks
Quest Diagnostics has been buying back its own shares.
- Latest authorization
- $1.00B, Feb 10, 2026
- Bought back, quarter ended Jun 30, 2026
- $102.0M
- As a share of market cap
- 0.37%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds DGX.
0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Quest Diagnostics earnings: next date and track record
Quest Diagnostics reports on Oct 20, 2026, before the open (30 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Oct 20, 2026
Expected before the open, 30 days away
- EPS estimate
- $2.85
- Revenue estimate
- $3.04B
8 of 8reports beat the EPS estimate
±6%average move across the report
7 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 23, 2026 AI summary
- What they said
- Quest Diagnostics reported Q2 2026 revenue growth of over 10% driven by broad clinical demand and volume from Corewell Health and Fresenius Medical Care collaborations. Adjusted diluted EPS grew over 19% year-over-year. Physician channel delivered high single-digit revenue growth while hospital channel grew at double-digit rates. The company is deploying automation and AI to improve productivity and quality across operations.
- Guidance
- Management raised full-year guidance for the second time, citing strong strategic execution and favorable demographic and technological trends driving sustained demand. Specific updated revenue and EPS targets were not detailed in the excerpt provided.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 23, 2026 | $3.12 est $2.81 | $3.04B est $2.97B | +8.6% |
| Apr 21, 2026 | $2.50 est $2.37 | $2.90B est $2.83B | +3.9% |
| Feb 10, 2026 | $2.42 est $2.36 | $2.81B est $2.75B | +9.4% |
| Oct 21, 2025 | $2.60 est $2.50 | $2.82B est $2.74B | −4.9% |
| Jul 22, 2025 | $2.62 est $2.57 | $2.76B est $2.73B | +2.4% |
| Apr 22, 2025 | $2.21 est $2.15 | $2.65B est $2.63B | +7.2% |
| Jan 30, 2025 | $2.23 est $2.18 | $2.62B est $2.58B | +4.9% |
| Oct 22, 2024 | $2.30 est $2.26 | $2.49B est $2.43B | +6.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Quest Diagnostics stock forecast and analyst price targets
Analysts’ average 12-month price target for Quest Diagnostics is $246.73, +0.1% from the last close, from 11 firms rating the stock in the last 90 days.
$246.73consensus 12-month target, +0.1% from the last close
Now $246.45Avg $246.73
Low $245High $265
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 8 | UBS | $245 | −0.6% |
| Sep 8 | UBS | $245 | −0.6% |
| Aug 19 | Morgan Stanley | $260 | +5.5% |
| Jul 28 | Argus Research | $260 | +5.5% |
| Jul 28 | Mizuho Securities | $260 | +5.5% |
+1.3%average 20-day move after past Neutral readings
−1.5%average move over the next 20 trading days in the last 5 years
±2.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Quest Diagnostics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Quest Diagnostics averaged −1.5% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.9% | 1 of 5 |
| Next 10 trading days | −3.0% | 0 of 5 |
| Next 15 trading days | −3.1% | 1 of 5 |
| Next 20 trading days | −1.5% | 2 of 5 |
| Next 30 trading days | +1.9% | 3 of 5 |
For scale, DGX’s typical 20-trading-day move in either direction is about 4%.
Quest Diagnostics market cap and key statistics
Quest Diagnostics’s market cap is $27.20B, with a P/E ratio of 26.3 and revenue of $11.56B over the last twelve months.
Valuation
- Market cap
- $27.20B
- P/E ratio
- 26.3
- Forward P/E
- 20.6
- EPS, TTM
- $9.41
- Gekko Fair Value
- $219.23
Trading
- Volume
- 1.93M
- Avg volume, 20 days
- 996,869
- 52-week high
- $248.70
- 52-week low
- $171.18
- Shares outstanding
- 110.4M
Financials
- Revenue, TTM
- $11.56B
- Profit margin
- 9.2%
- Return on equity
- 14.6%
- Quarterly earnings growth, YoY
- +15.0%
Risk and income
- Beta
- 0.55
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4%
- Dividend yield
- 1.34%
Quest Diagnostics stock news this week
6 headlines about Quest Diagnostics from the past week, newest first, each linking to the publisher.
- Corient Private Wealth LP Sells 5,233 Shares of Quest Diagnostics Incorporated $DGXDefense World, Sep 18
- Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research, Sep 16
- Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest DiagnosticsPRNewsWire, Sep 16
- Quest Diagnostics (NYSE:DGX) Reaches New 52-Week High – Time to Buy?Defense World, Sep 16
- Quest Diagnostics Incorporated (DGX) Presents at 2026 Global Healthcare Conference TranscriptSeeking Alpha, Sep 15
- Quest Diagnostics (DGX) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research, Sep 14
Quest Diagnostics peers
Quest Diagnostics’s 2 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| ASTHAstrana Health | Buying | 34.9% below |
| NRCNational Research | Accumulation | 5.9% above |
A peer links to its own page where one exists.
Quest Diagnostics stock FAQ
What is Quest Diagnostics’s market cap?
Quest Diagnostics’s market cap is $27.20B at the Sep 18, 2026 close of $246.45, with 110.4M shares outstanding. The shares trade on a P/E ratio of 26.3.
What is the Quest Diagnostics stock forecast?
The consensus analyst 12-month price target for Quest Diagnostics is $246.73, +0.1% from the last close. Of the 11 firms that rated the stock in the last 90 days, 7 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Quest Diagnostics stock overvalued or undervalued?
On Gekko’s estimate Quest Diagnostics is overvalued: the Sep 18, 2026 close of $246.45 is 12.4% above Gekko Fair Value of $219.23. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Quest Diagnostics report earnings next?
Quest Diagnostics is expected to report on Oct 20, 2026, before the market opens (30 days away). Analysts expect earnings of $2.85 per share on revenue of $3.04B. Quest Diagnostics beat the earnings estimate in 8 of its last 8 reports, moving 6% on average across the report.
What is Quest Diagnostics’s 52-week high and low?
Quest Diagnostics’s 52-week high is $248.70 and its 52-week low is $171.18; it closed at $246.45 on Sep 18, 2026, +35.2% over the past year.
Is Quest Diagnostics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Quest Diagnostics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.